Uncategorized
Patients report adalimumab for uveitis improves quality of life
A post hoc analysis of pivotal multicenter trials evaluating adalimumab as a treatment for uveitis showed meaningful patient-reported improvement in visual functioning and vision-related quality of life. Adalimumab is an anti-inflammatory drug approved for the treatment of noninfectious intermediate uveitis, posterior uveitis and panuveitis. It was tested in the VISUAL-1 and VISUAL-2 phase 3 placebo-controlled trials in patients with, respectively, active and inactive uveitis previously treated with oral corticosteroid therapy. In the trials, adalimumab showed efficacy in lowering the risk for uveitic flare and vision loss.